Ask about this productRelated genes to: ASXL1 antibody
- Gene:
- ASXL1 NIH gene
- Name:
- ASXL transcriptional regulator 1
- Previous symbol:
- -
- Synonyms:
- KIAA0978
- Chromosome:
- 20q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 2002-03-06
- Date modifiied:
- 2019-04-23
Related products to: ASXL1 antibody
Related articles to: ASXL1 antibody
- : Acute myeloid leukemia (AML) with myelodysplasia-related gene mutations (AML-MR), often referred to as secondary AML (s-AML) or AML-MRC, is an aggressive form of leukemia that typically arises from an antecedent myelodysplastic syndrome (MDS) but may also originate de novo. It is characterized by mutations in key genes associated with MDS that include some epigenetic regulators ( and ), splicing factors (, , , and ), and transcription factors (, , and ). The main objective of this review paper consists of analyzing recent studies that have improved the criteria for the characterization, definition, and classification of AML-MR. : An extensive search of the most recent literature on the topic was performed, selecting and critically analyzing the most relevant studies. . The studies carried out in the last few years have provided an extensive molecular characterization of AML-MR, supporting sounder criteria for identification and a better definition with respect to other AML subtypes, particularly with respect to -mutant AML. : A unifying classification of AML-MR is now possible, allowing its identification as a unique, well-defined, and separate entity. - Source: PubMed
Publication date: 2026/07/30
Testa Ugo - Post-treatment erythrocytosis (PT-E)-an increase in red blood cell counts after therapy-is an uncommon but reproducible finding in a subset of Hodgkin lymphoma (HL) survivors, and its biological basis remains undefined. - Source: PubMed
Publication date: 2026/08/05
Koyun DeryaYüksel SeherCivriz Bozdağ SinemTuncalı TimurKuzu IşınsuÖzcan Muhit - Myeloproliferative neoplasms (MPNs) are chronic myeloid malignancies characterized by substantial genetic heterogeneity. Although routine molecular evaluation focuses on canonical driver alterations (, , , and ), additional somatic mutations have important diagnostic and prognostic implications. - Source: PubMed
Publication date: 2026/07/31
Tizro ParastouVail EricSapkota ManojGayhart Matthew GEno Celeste C - Azacitidine-venetoclax (AZA-VEN) has become a standard treatment in older or chemotherapy-ineligible AML patients. While the registration trial showed a median overall survival (OS) of 14.7 months, most real-world studies have not reproduced this result. - Source: PubMed
Publication date: 2026/07/17
Lapierre LéopoldineLaemmel LucieBérard EmilieRigolot LucieBidet AudreyHigué JulesBanos AnneBéziat GuillaumeJeddi RamziBranco BenoitCalmettes ClaireGadaud NoémieGauthier MartinGhenim LeilaLaboure GaelleSalvado ClémentineTabrizi RezaThomazeau JoséphineVaillant WillyTavitian SuzanneBalardy LaurentLeguay ThibautCanali AlbanKlein EmilieSarry AudreyMougenot MadelineBaraniecki Evade Grande Anne-CharlotteBories PierreLargeaud LaetitiaHeiblig MaëlBelhabri AmineTauveron-Jalenques UrbainTavernier EmmanuelleCarré MartinPigneux ArnaudVergez FrançoisBertoli SarahDumas Pierre-YvesRécher Christian - Clonal hematopoiesis (CH) is associated with cardiovascular disease (CVD), inflammation, and increased mortality. However, its prevalence and clinical impact in patients with cytopenia and chronic kidney disease (CKD) remain unclear. - Source: PubMed
Publication date: 2026/08/12
Yaophrukchai SuwannapornPolprasert ChantanaKobbuaklee SiroratRojnuckarin PonlapatKongkiatkamon Sunisa